Status Epilepticus

Author: Adam Reuben / Editor: Steve Fordham / Reviewer: Joe Schrieber / Codes: CAP15, HAP15Published: 30/10/2017

Context and Definition

Status epilepticus (SE), a state of prolonged, uncontrolled seizures, is a common emergency department (ED) presentation that is potentially life-threatening. Untreated, the mortality approaches 30%, whilst following evidence based, validated treatment algorithms can significantly improve outcomes. Presentations may vary from clinically obvious tonic-clonic convulsions, to subtle focal seizures, to seemingly bizarre sensory alterations associated with partial seizures. An awareness of the existence and extreme presentations of these different forms is required.

SE is a prolonged seizure of any type.

Traditional definitions of SE refer to either:

  • A single seizure persisting for greater than 30 minutes
  • Multiple seizures of shorter duration without a full neurological recovery in between seizures

There is a growing body of support for the definition to refer to seizures that persist for greater than 5 minutes without intervention [1-6]. This relates to evidence demonstrating that a significant proportion of seizures that continue for 5 minutes will go on to persist for greater than 30 minutes and that the average seizure duration in adults is less than 1 minute. Hence, seizures that persist beyond 5 minutes represent a significant deviation away from the norm. Further to this, there is a suggestion that neuronal injury can result after just 5 minutes of seizure activity.

More recently the use of the term impending status epilepticus has been advocated to describe continuous or intermittent seizures that persist beyond 5 minutes without neurological recovery [6]. This definition recognises the immediate requirement for treatment for such patients, but acknowledges that not all are in established SE and that up to 40% of these may terminate spontaneously within 30 minutes.

Established SE refers to clinical or electrographic seizures that persist for 30 minutes or longer without full neurological recovery in between.

Refractory SE is defined as the persistence of convulsions despite adequate doses of two intravenous agents.

SE may be subdivided into convulsive and non-convulsive forms. These will be discussed in greater detail.

Basic Science and Pathophysiology

Seizures result from rapid abnormal electrical discharges from cerebral neurones. This is thought to arise from an imbalance between excitatory and inhibitory neurotransmitters (most commonly between Glutamate and GABA) leading to a failure of the inhibitory process [7].

Numerous systemic and metabolic changes occur in association with prolonged seizures; these include tachycardia, hypertension, hyperglycaemia and lactic acidosis. Most of these are thought to result from a surge in catecholamine release that accompanies the seizure and will resolve with seizure resolution. Beyond 30 minutes of seizure duration cerebral autoregulation may become impaired and cerebral perfusion will fall as hypotension occurs with potential for ischaemic injury and cerebral oedema.


The underlying aetiology of SE can be divided into 3 groups:

  • 1/3 of patients will have an underlying background of chronic epilepsy
  • 1/3 of patients the episode will represent the onset of future epilepsy
  • 1/3 of patients the episode occurs with no prior or future history of epilepsy

In patients with a pre-existing history of epilepsy, SE most commonly results from drug non-compliance or withdrawal or alteration of drug therapy, but it may also occur in the presence of intercurrent illness, metabolic abnormalities or the co-ingestion of drugs which lower the seizure threshold [4]. In the absence of an established diagnosis of epilepsy, SE may result from drug withdrawal syndromes (alcohol, barbiturates, benzodiazepines), acute structural brain injury (eg stroke, subarachnoid haemorrhage, trauma, cerebral hypoxia) or CNS infection (meningitis, encephalitis, abscess).

Clinical Assessment and Risk Stratification

There are numerous different forms of SE, classification being important to help direct the appropriate level of treatment and investigation.

Broadly speaking, SE may be categorised as being either convulsive or non-convulsive, depending on the presence or absence of regular focal or generalised contractions of the muscles. Convulsive status may be further classified as generalised (involving the entire brain) or partial (involving only part of the brain) [7]. However, other classifications do exist.

a) Generalised Tonic-Clonic SE:

Often the most clinically obvious presentation of SE. it begins with a sudden powerful contraction of the muscles (tonic phase) often associated with a fall to the floor, followed by regular rhythmic contraction and relaxation (clonic phase) of the musculature of all limbs. This is invariably associated with alterations in the level of consciousness.

b) Partial SE:

Defined by seizures originating from a specific area of the cortex without any impairment of consciousness. Presentation may be far more subtle than for generalised seizures and may involve motor (regular rhythmic contractions of a single limb or muscle group) or sensory (illusions, hallucinations, depersonalisation) symptoms.

Complex partial seizures are associated with a degree of conscious impairment and arise from a single region of the brain. Symptoms may include aphasia, apraxia and focal limb weakness. They may often be associated with motor or verbal automatisms.

Other forms of status epilepticus exist, but are less frequent. These include absence, myoclonus, or pseudo-status epilepticus, the latter characterised by tonic clonic jerks in the absence of true altered consciousness.

All ED patients with SE should have an intravenous cannula sited and blood sent for urea, electrolytes, magnesium, calcium and full blood count. A blood gas, either venous or arterial is useful for demonstration of the patients metabolic status. Further investigations will be dictated according to the specific circumstances of individual cases. These may include a CT brain, blood cultures, serum anticonvulsant levels and lumbar puncture for CSF evaluation [2,4]. An electroencephalogram (EEG) is rarely required in the acute setting; however it may be of value in patients with suspected non-convulsive status, or in those patients who are paralysed and sedated [8]. Clear ictal activity may not be seen on the EEG during simple partial status epileptics.

Status epilepticus is a medical emergency that requires urgent aggressive therapy in order to limit any long term damage. The following principles are key:

  • Early initiation of anticonvulsants is key to successful treatment
  • Outcomes worsen with increasing duration of SE
  • Loss of responsiveness to benzodiazepines will occur with time


Treatment should begin with attention to airway, breathing and circulation, with the application of high flow oxygen where available. Blood glucose should be checked and intravenous dextrose used to treat hypoglycaemia as indicated.

There is a good amount of evidence to support the use of benzodiazepines in the pre-hospital setting. Either Diazepam (rectal) or Midazolam (buccal or intranasal) may be used for this purpose [9].


The following agents may be used in the management of patients with SE:

1. Benzodiazepines

This group represents the first line of agents for treating SE, preventing the propagation of the seizure rather affecting the original focus [10]. All have a rapid onset of action due to their lipid solubility and ability to cross the blood brain barrier. The agents used most frequently are Diazepam, Lorazepam and Midazolam. Both Diazepam and Lorazepam are lipid soluble, the former being available as both intravenous and rectal preparations. Rectal Diazepam will terminate seizures in 70% of patients, intravenous Diazepam will terminate seizures in 60-80% of patients in SE. Lorazepam is less lipophillic, has a smaller volume of distribution and a longer intracerebral half life (12 hours) than Diazepam and hence may provide more prolonged suppression of seizures. Intravenous Lorazepam will terminate seizures in 60-90% of patients in SE. Midazolam is water soluble making it available for buccal or intranasal use, primarily in the pre-hospital setting. All benzodiazepines carry the risk of respiratory depression and hypotension.

2. Hydantoins

Phenytoin is a long acting drug whose advantage is the prevention of seizure recurrence over an extended period of time. Its delayed onset (10 to 30 minutes) necessitates use in combination with a rapidly acting agent, typically a benzodiazepine. Phenytoin is not water soluble and is formulated with propylene glycol which is associated with the potential for significant side-effects including local infusion site reactions, arrhythmias and hypotension mandating cardiac monitoring during infusion. Phenytoin is associated with the purple glove syndrome characterised by local oedema, skin discolouration and pain distal to the infusion site. Skin necrosis and limb ischemia have been reported. Complications are reduced by keeping infusion rates below 50 mg per minute and by avoiding co-infusion with dextrose containing fluids which can lead to the formation of precipitates.

Fosphenytoin is the inactive prodrug of Phenytoin which is broken down into the active drug by serum phosphatases. It has the advantage that it is water soluble and hence is associated with fewer of the local side-effects. It may also be infused at a faster rate, however the time taken for the active metabolite to be formed means that the time taken to achieve therapeutic Phenytoin levels is similar for both.

3. Paraldehyde

Paraldehyde is recommended in many treatment algorithms as a second-line agent to be used after benzodiazepines, in the absence of intravenous access. It is given via the rectal route mixed with an equal volume of olive oil. Whilst there is little evidence to support its use, there is a large body of anecdotal evidence.

4. Barbiturates

Have a similar mode of action to benzodiazepines by modification of the actions of GABA. These agents are not standard first-line drugs, but may be used for patients with refractory status epilepticus. Side-effects include respiratory depression and sedation particularly if used after benzodiazepines. Agents used include Phenobarbital, Thiopental and Pentobarbital. The latter is a short-acting agent with a rapid onset of action that is very effective at terminating seizures.

5. Other agents

The evidence base for the use of other agents outside of the first-line drugs is limited; hence numerous other drugs are used for the treatment of refractory SE without any clear standardisation. These include:

  • Propofol is an intravenous anaesthetic agent with rapid onset and short duration of action that has been shown to be effective in terminating seizures. Use is limited in children due to a risk of propofol infusion syndrome not seen in adults and also by hypotension resulting from the high doses required to produce burst suppression on the EEG
  • Levetiracetam is a new antiepileptic drug, with a unique pharmacological profile not metabolised in the liver [11]. This has been shown to be a useful adjunct in the treatment of refractory SE in several case series, having the benefit of causing less cardiovascular and respiratory depression than other agents
  • Midazolam whilst often used as a first-line agent, particularly in the pre-hospital setting, Midazolam may also be useful for the treatment of refractory SE. it has been shown to be capable of rapidly controlling seizures when given as a continuous infusion

Treating all convulsions as status epilepticus and instituting early intravenous therapy. The majority of seizures will be self-limiting and will cease spontaneously within 5 minutes.

Prescribing intravenous sodium bicarbonate for patients in status epilepticus with a profound metabolic acidosis. This acidosis will usually resolve spontaneously and may contribute to the cessation of convulsions.

Failure to treat patients with convulsions on the basis that they may actually represent pseudo-seizures. It represents a far greater danger to fail to treat a patient who may have genuine status epilepticus than it does to treat the converse situation.

To leave too short a time for an agent to have its effect before instituting treatment with a further agent. This may compound any adverse effects. For patients with impending status epilepticus 10 minutes should be allowed between subsequent drug doses.

Key Learning Points

  • Status epilepticus refers to a single seizure lasting 30 minutes or longer, or multiple shorter seizures without full neurological recovery in between
  • Impending status epilepticus may be used to refer to multiple or continuous seizures lasting 5 minutes or more without full neurological recovery in between (Grade C)
  • Two thirds of patients with status epilepticus will have no prior history of epilepsy or convulsions (Grade C)
  • In patients with epilepsy, status epilepticus most commonly results from reduced intake of normal anti-epileptic medication (Grade C)
  • Status epilepticus may be classified as being convulsive or non-convulsive, with the former being further subdivided into general or partial seizures
  • After 30 minutes of seizure activity there may be failure of cerebral autoregulation with potential for ischaemia and oedema
  • An Venous Blood Gas should be taken in all patients with status epilepticus, but it should be remembered that significant metabolic abnormalities are common following prolonged seizures and these will usually normalise following seizure termination (Grade D)
  • Intravenous benzodiazepines will terminate seizures in over 80% of patients in a matter of minutes and hence should act as first line agents (Grade B)
  • Lorazepam is more effective at terminating seizures than diazepam and is more effective at preventing seizure recurrence (Grade A)
  1. Knake S, Hamer HM, Rosenow F. Status epilepticus: A critical review. Epilepsy Behav 2009 (in press)
  2. Marik PE, Varon J. The management of status epilepticus. Chest 2004;126:582-591.
  3. Bassin S, Smith TL, Bleck TP. Clinical review: Status epilepticus. Crit Care 2002;6:137-142.
  4. Walker M. Status epilepticus: an evidence based guide. BMJ 2005;331:673-677.
  5. Watson C. Status epilepticus: Clinical features, pathophysiology and treatment. West J Med 1991;155:626-631.
  6. Chen JWY, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5:246-256.
  7. Basu H, OCallaghan F. Status epilepticus: beyond the guidelines. Curr Paeditrics 2005;15:324-332.
  8. Varelas PN, Spanaki MV, Hacein-Bey L et al. Emergent EEG: indications and diagnostic yield. Neurology 2003;61:702-704.
  9. Rainbow J, Browne GJ, Lam LT. Controlling seizures in the prehospital setting: diazepam or midazolam? J Paediatr Child Health 2002;38(6):582-586.
  10. Lockey AS. Emergency department drug therapy for status epilepticus in adults. EMJ 2002;19:96-100.
  11. Patel NC, Landan IR, Levin J et al. The use of levetiracetam in refractory status epilepticus. Seizure 2006;15:137-141.


  1. elsheikhm says:

    This is really good

  2. Ashleigh Lowther says:

    Great learning session- Interested to hear peoples thoughts on Levetiracetam I am hearing lots of things on that being higher up the pecking order than phenytoin? Thoughts?

  3. Catherine Taylor says:

    Great bite size learning session

  4. Dr. Charles Raymond-Orororo says:

    brief and concise

  5. Dr. Altaf Hussain Khan says:


  6. eldenlees says:

    Really good session with clear explanation of drug choices and actions.

Leave a Reply